As scientists race to develop treatments and vaccines for the COVID-19 virus, one facility in London is looking for volunteers to be infected with a coronavirus to help with research. hVIVO, an arm of a pharmaceutical company based in the U.K. capital, is looking for 24 people to be infected with common strains of a member of the large coronavirus family of pathogens which the new coronavirus is also a member of. The bug isn’t the same as the COVID-19 virus, but close enough for biotechnology and pharmaceutical companies to safely test vaccines and antiviral drugs to fight the new coronavirus on participants. The volunteers will be paid £3,500 ($4,380) according to The Times. To qualify, they must be must be healthy, aged between 18-55 years old, non-smokers, and have a verifiable medical history, Cathal Friel, executive chairman of Open Orphan, the company of which hVIVO is a subsidiary, told Newsweek. To keep participants safe, the team will use strains like OC43 and 229E, which have been widespread “for many years and cause only a mild cold-like respiratory illness” according to a statement by hVIVO. The catch? Participants must be comfortable with being quarantined for up to 14 days at… Read full this story
- Mumps - Causes-Symptoms and Treatment
- New Treatments For Prostate Cancer
- Is Homeopathic Treatment of Influenza Safe or Effective?
- How Was The Treatment Of Tuberculosis Discovered?
- Obesity Vaccine - A Cure to the Epidemic?
- Do You Want a Natural Remedy for Yeast Infections?
- Reoccurring Yeast Infections - Is There a Natural Solution?
- How Magnet Therapy Can Help Stem The Tide of The Hidden Chronic Fatigue Epidemic
- Immunomodulators, a Stop to Infections?
- Natural Urinary Tract Infection Cure - Is Natural Health the New Starbucks?
Scientists in London Paying People $4,000 to Get Infected With Coronaviruses to Help Find COVID-19 Vaccine and Treatments have 281 words, post on www.newsweek.com at March 12, 2020. This is cached page on Movie Breaking News. If you want remove this page, please contact us.